Trial Profile
A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-Positive Breast Tumor.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Letrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms GETNA-2
- Sponsors Sanofi
- 03 Mar 2008 New trial record.